Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Medications listed in higher drug tiers will generally have higher copays and out-of-pocket costs
Semaglutide injection 2.4 mg carries a Boxed Warning for possible thyroid tumors, including cancer, and should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Greater reductions in HbA1c (around 1.21.6% vs 0.8%) Up to 80% of patients achieved HbA1c below 7% (vs around one-third) More weight loss (6.37.3% vs 3.0%) Improvements in triglycerides, non-HDL cholesterol and systolic blood pressure Most importantly, orforglipron demonstrated superior glycaemic control compared with dapagliflozin
Additionally, bodybuilders often stack multiple performance-enhancing substances, and combining semaglutide with anabolic steroids or other drugs substantially increases cardiovascular and metabolic complications
